Across TCGA pan-cancer cohorts, HMGB1P17 RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated HMGB1P17 data layer.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher HMGB1P17 RNA is associated with better overall survival. In most high-consensus cancer types, elevated HMGB1P17 expression acts as an unfavorable survival marker, although some lineages such as STAD and SKCM show a favorable association.
STAD, SKCM, and CESC are the cancer types where HMGB1P17 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.